Close Menu

investment analyst coverage

Talis, which went public last month, develops point-of-care infectious disease tests based on its flagship Talis One sample-to-answer platform.

Danaher’s guidance of double-digit top-line growth for 2021 provides upside opportunities that depend mostly on the success of vaccine rollouts, Barclays said.

The investment bank cited its expectation for a positive coverage decision from Medicare for the company's SelectMDx prostate cancer test, among other reasons.

The investment bank said that Lucira's COVID-19 single-use test could have widespread use with potential for adoption in the over-the-counter markets.

Piper Sandler analyst Steven Mah noted that Ortho's installed base of more than 20,000 instruments provide it with 93 percent recurring revenue.

In a survey, analysts found that reimbursement and test awareness were major barriers to driving adoption of the firm's assay for identifying skin cancer.

The investment bank highlighted the technology underlying DermTech's non-invasive, skin patch-based melanoma test as key to its future growth.

BTIG highlighted the firm's cancer test portfolio, as well as its growing position in the liquid biopsy and minimal residual disease testing space.

The investment bank sees the potential for strong revenue growth over time as Oncocyte expands its product portfolio and launches new tests.

William Blair, Canaccord Genuity, and BTIG on Monday initiated coverage of newly public Biodesix, with ratings ranging from Buy to Outperform.